The study found, according to a press release, a 49 percent savings for self-funded employer groups, amounting to $1.3 million in savings every year.
The Regenexx process involves using cells from an individual’s own body to treat common orthopedic conditions, with physicians giving precise injections using platelet-rich plasma and bone marrow.
“Overuse and misuse of orthopedic surgery is prevalent in our healthcare system today. Our regenerative orthopedic approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime,” Regenexx Corporate Program Founder Jason Hellickson said in the July 19 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
